Gyrase-inhibitors impair caffeine elimination in man.
D000328:Adult; D002110:Caffeine / Q000378:metabolism*; D002939:Ciprofloxacin / Q000494:pharmacology*; D004347:Drug Interactions; D015365:Enoxacin; D006801:Humans; D007700:Kinetics; D008297:Male; D009287:Naphthyridines / Q000494:pharmacology*; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology*; D059005:Topoisomerase II Inhibitors
D009287:Naphthyridines; D010078:Oxazines; D059005:Topoisomerase II Inhibitors; D015365:Enoxacin; D002110:Caffeine; D002939:Ciprofloxacin; D015242:Ofloxacin